Concerning the role of methylation in resistance to EGFR ΤΚΙ therapy, there are now studies performed in lung cancer cell lines or primary tissues showing that epigenetic modifications negatively affect EGFR TKI treatment outcome and that their combination with epigenetic drugs could be very promising (109–115). This evidence concerns the gene EGFR and lung cancer.